Successful treatment of acute portal vein thrombosis with rivaroxaban

Thromb Haemost 2013; 110(04): 626-627
DOI: 10.1160/TH13-05-0407

T&H Images

Schattauer GmbH

Authors

Sven Pannach

¹Division Gastroenterology, Medical Clinic I, Dresden University Hospital “Carl Gustav Carus”, Dresden, Germany
Jana Babatz

¹Division Gastroenterology, Medical Clinic I, Dresden University Hospital “Carl Gustav Carus”, Dresden, Germany
Jan Beyer-Westendorf

²Center for Vascular Diseases and Medical Clinic III, Dresden University Hospital “Carl Gustav Carus”, Dresden, Germany

References
1 Thatipelli MR, McBane RD, Hodge DO. et al. Survival and recurrence in patients with splanchnic vein thromboses. Clin Gastroenterol Hepatol 2010; 8: 200-205.
2 Kearon C, Akl EA, Comerota AJ. et al. Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141 (Suppl. 02) e419S-e94S.
3 Riva N, Donadini MP, Dentali F. et al. Clinical approach to splanchnic vein thrombosis: risk factors and treatment. Thromb Res 2012; 130 (Suppl. 01) S1-S3.
4 Turpie AG, Kreutz R, Llau J. et al. Management consensus guidance for the use of rivaroxaban--an oral, direct factor Xa inhibitor. Thromb Haemost 2012; 108: 876-886.
5 Hammerstingl C, Potzsch B, Nickenig G. Resolution of giant left atrial appendage thrombus with rivaroxaban. Thromb Haemost 2013; 109: 583-584.